西班牙采集的葡萄球菌血分离株的 TR-700（替考拉宁）比较活性。
Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
机构信息
Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.
Abstract
The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates. TR-700 showed excellent activity against all the staphylococci tested. The MIC(50) and MIC(90) values of TR-700, linezolid, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) isolates were 0.25 and 0.5, 2 and 4, 0.5 and 0.5, and 1 and 2 microg/ml, respectively. TR-700 demonstrated greater in vitro potency than linezolid against staphylococci, including linezolid-resistant and vancomycin-nonsusceptible strains, and was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested.
摘要
TR-700（替唑利定）的体外活性对 660 株葡萄球菌血培养分离株进行了评估。TR-700 对所有测试的葡萄球菌均表现出优异的活性。TR-700、利奈唑胺、达托霉素和万古霉素对耐甲氧西林金黄色葡萄球菌（MRSA）分离株的 MIC（50）和 MIC（90）值分别为 0.25 和 0.5、2 和 4、0.5 和 0.5、1 和 2μg/ml。TR-700 对葡萄球菌的体外效力大于利奈唑胺，包括利奈唑胺耐药和万古霉素不敏感株，对 7 株 cfr 阳性 MRSA 株的活性比利奈唑胺高 32 倍。
相似文献
1
Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.
2
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
3
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.
4
In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
J Microbiol Immunol Infect. 2011 Oct;44(5):346-51. doi: 10.1016/j.jmii.2011.01.037. Epub 2011 Jan 20.
5
In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.
J Antimicrob Chemother. 2012 Jan;67(1):167-9. doi: 10.1093/jac/dkr403. Epub 2011 Sep 27.
6
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
Antimicrob Agents Chemother. 2011 Jul;55(7):3453-60. doi: 10.1128/AAC.01565-10. Epub 2011 Apr 18.
7
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Int J Antimicrob Agents. 2014 Apr;43(4):323-7. doi: 10.1016/j.ijantimicag.2013.11.005. Epub 2013 Dec 11.
8
In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Antimicrob Agents Chemother. 2012 Sep;56(9):4608-13. doi: 10.1128/AAC.00458-12. Epub 2012 Jun 11.
9
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Aug;52(8):2974-6. doi: 10.1128/AAC.00257-08. Epub 2008 Jun 2.
10
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).
Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.
引用本文的文献
1
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
2
In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections.
Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1549-1552. doi: 10.1007/s10096-017-2966-z. Epub 2017 Mar 22.
3
Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):331-337. doi: 10.1080/17425255.2017.1290080. Epub 2017 Feb 16.
4
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7.
5
Tedizolid phosphate.
Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961.
6
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013.
7
Newer antibacterials in therapy and clinical trials.
N Am J Med Sci. 2012 Nov;4(11):537-47. doi: 10.4103/1947-2714.103312.
8
Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.
9
In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Antimicrob Agents Chemother. 2012 Sep;56(9):4608-13. doi: 10.1128/AAC.00458-12. Epub 2012 Jun 11.
10
Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.
Antimicrob Agents Chemother. 2012 May;56(5):2342-6. doi: 10.1128/AAC.06427-11. Epub 2012 Feb 21.
本文引用的文献
1
Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.
Clin Infect Dis. 2010 Mar 15;50(6):821-5. doi: 10.1086/650574.
2
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.
3
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.
Antimicrob Agents Chemother. 2009 Dec;53(12):5275-8. doi: 10.1128/AAC.01032-09. Epub 2009 Oct 5.
4
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).
Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.
5
In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
Antimicrob Agents Chemother. 2009 Aug;53(8):3236-9. doi: 10.1128/AAC.00228-09. Epub 2009 Jun 15.
6
ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
Diagn Microbiol Infect Dis. 2009 Jun;64(2):191-201. doi: 10.1016/j.diagmicrobio.2009.03.001.
7
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
J Antimicrob Chemother. 2009 Apr;63(4):716-20. doi: 10.1093/jac/dkp021. Epub 2009 Feb 13.
8
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
J Antimicrob Chemother. 2009 Apr;63(4):713-5. doi: 10.1093/jac/dkp002. Epub 2009 Jan 22.
9
In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.
Antimicrob Agents Chemother. 2008 Dec;52(12):4442-7. doi: 10.1128/AAC.00859-08. Epub 2008 Oct 6.
10
First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.
Antimicrob Agents Chemother. 2008 Jun;52(6):2244-6. doi: 10.1128/AAC.00231-08. Epub 2008 Apr 7.
Zotero 插件